"We Know We Will Emerge Stronger In The U.S.," Says Ranbaxy CEO Atul Sobti: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Now under majority ownership by Daiichi Sankyo the Indian drug maker is revisiting its U.S. business model, with "very innovative" plans for generics, OTC and branded drugs, Sobti says.